Document is current
Any future updates will be listed below
-
Authors
Zamberlan, Margherita
Boeckx, Amandine
Muller, Florian
Vinelli, Federica
Ek, Olivier
Vianello, Caterina
Coart, Emeline
Shibata, Keitaro
Christian, Aurélie
Grespi, Francesca
Giacomello, Marta
Struman, Ingrid
Scorrano, Luca https://orcid.org/0000-0002-8515-8928
Herkenne, Stéphanie
-
Funding
Funding for this research was provided by:
Associazione Italiana per la Ricerca sul Cancro (ig19991)
Fondazione Cassa di Risparmio di Padova e Rovigo (SIGMI)
Ministero dell’Istruzione, dell’Università e della Ricerca (2017BF3PXZ)
- License Information
-
More Information
Article History
Received: 31 October 2021
Accepted: 26 February 2022
First Online: 12 March 2022
Declarations
:
: All in vivo experiments were approved by the local Animal Ethic Commission (File number 2166, “Commission d’éthique de l’utilisation des animaux de l’Université de Liège”).
: Not applicable.
: LS is an inventor in the PCT/EP2019/068846 on MYLS22 as an anticancer drug. All other authors declare no competing interest.
